New Zealand markets close in 29 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.85+0.18 (+2.70%)
At close: 04:00PM EDT
6.88 +0.03 (+0.44%)
After hours: 07:17PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 443.90M
Enterprise value 518.23M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.63
Price/book (mrq)74.89
Enterprise value/revenue 7.68
Enterprise value/EBITDA -2.57

Trading information

Stock price history

Beta (5Y monthly) 0.27
52-week change 3-49.56%
S&P500 52-week change 3-2.16%
52-week high 314.42
52-week low 33.28
50-day moving average 36.20
200-day moving average 35.71

Share statistics

Avg vol (3-month) 3782.06k
Avg vol (10-day) 3895.33k
Shares outstanding 566.55M
Implied shares outstanding 6N/A
Float 859.79M
% held by insiders 10.92%
% held by institutions 185.25%
Shares short (28 Jul 2022) 412.52M
Short ratio (28 Jul 2022) 423.14
Short % of float (28 Jul 2022) 427.21%
Short % of shares outstanding (28 Jul 2022) 419.38%
Shares short (prior month 29 Jun 2022) 411.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)-286.70%

Management effectiveness

Return on assets (ttm)-41.38%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)67.49M
Revenue per share (ttm)1.44
Quarterly revenue growth (yoy)-53.70%
Gross profit (ttm)-41.74M
EBITDA -192.88M
Net income avi to common (ttm)-257.56M
Diluted EPS (ttm)-6.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)185.84M
Total cash per share (mrq)2.79
Total debt (mrq)536.12M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.07
Book value per share (mrq)-4.52

Cash flow statement

Operating cash flow (ttm)-216.4M
Levered free cash flow (ttm)-156.74M